It’s common for patients to want to know more about what’s causing them to be ill and their DMD diagnosis and it’s the same for their families – however long that road may be.
Summit Therapeutics has axed development of its Duchenne muscular dystrophy drug ezutromid after a spectacular failure in phase 2, causing the UK biotech's shares to plunge.
Everyone wants to find a cure for a debilitating long-term condition, but what can often be overlooked is the value in being able to first make life more manageable, comfortable or enjoyabl
